| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
NSC727447 targets ribonuclease H (RNase H) of HIV-1 and HIV-2. RNase H is an essential enzyme in the HIV life cycle that degrades the RNA strand of the RNA-DNA hybrid formed during reverse transcription, allowing for second-strand DNA synthesis. Inhibition of RNase H represents a validated but underexploited target for antiretroviral therapy.
|
|---|---|
| ln Vitro |
NSC727447 shows potent in vitro inhibition of HIV-1 and HIV-2 RNase H with IC₅₀ values of 2.0 μM and 2.5 μM, respectively. Notably, the compound has little activity against E. coli RNase H (IC₅₀ = 100 μM) and demonstrates approximately 5-fold selectivity over human RNase H (IC₅₀ = 10.6 μM). This selectivity profile is favorable for reducing off-target toxicity.
|
| ln Vivo |
In vivo activity of NSC727447 has not been extensively reported in the available literature. As an RNase H inhibitor with good selectivity for viral over human RNase H, the compound may have potential for antiretroviral therapy. However, further preclinical studies are needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile.
|
| Enzyme Assay |
Non-cell-based enzyme assays for NSC727447 typically involve measuring RNase H activity using fluorescence-based or radioactive substrates. A typical protocol includes: incubating purified RNase H enzyme (HIV-1, HIV-2, or human) with a fluorogenic RNA-DNA hybrid substrate, adding NSC727447 at various concentrations (0.1–100 μM), and measuring the decrease in fluorescence signal as a function of enzyme inhibition. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for NSC727447 typically involve HIV-infected cell lines. A representative protocol includes: culturing HIV-infected cells (e.g., MT-4 or CEM cells), treating with NSC727447 at various concentrations for 3–7 days, measuring viral replication by p24 antigen ELISA or RT activity assay, and assessing cell viability using MTT or similar assays to determine the therapeutic index.
|
| Animal Protocol |
In vivo animal studies with NSC727447 are limited as the compound appears to be in early-stage research. If conducted, a typical protocol might include: administering the compound via oral gavage or intraperitoneal injection in HIV-infected humanized mouse models, monitoring viral load, CD4+ T cell counts, and body weight, and assessing compound toxicity by histopathological examination of major organs.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of NSC727447 have not been extensively reported in the available literature. As a small molecule with a molecular weight of 210.30 g/mol and moderate lipophilicity, it is expected to have reasonable oral bioavailability and tissue penetration. Further PK studies are needed to characterize its absorption, distribution, metabolism, and excretion profile.
|
| Toxicity/Toxicokinetics |
Toxicological data for NSC727447 are limited as the compound is in research stages. The selectivity for viral over human RNase H (5-fold) suggests potential for a favorable safety margin, but comprehensive toxicology studies have not been reported. Standard safety precautions should be followed when handling the compound.
|
| References | |
| Additional Infomation |
NSC727447 (CAS 40106-12-5) is a promising HIV RNase H inhibitor with good selectivity over human and bacterial RNase H. RNase H remains an underexploited target for antiretroviral therapy, and NSC727447 represents a valuable tool compound for studying HIV RNase H inhibition. The compound is typically stored as a powder at -20°C for 3 years or 4°C for 2 years.
|
| Molecular Formula |
C10H14N2OS
|
|---|---|
| Molecular Weight |
210.30
|
| Exact Mass |
210.083
|
| CAS # |
40106-12-5
|
| PubChem CID |
2997881
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.278g/cm3
|
| Boiling Point |
347.5ºC at 760 mmHg
|
| Flash Point |
163.9ºC
|
| Index of Refraction |
1.639
|
| LogP |
2.979
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
14
|
| Complexity |
234
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1CCC2=C(CC1)SC(=C2C(=O)N)N
|
| InChi Key |
LULYZYNTDPUEKK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H14N2OS/c11-9(13)8-6-4-2-1-3-5-7(6)14-10(8)12/h1-5,12H2,(H2,11,13)
|
| Chemical Name |
2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~237.76 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7551 mL | 23.7756 mL | 47.5511 mL | |
| 5 mM | 0.9510 mL | 4.7551 mL | 9.5102 mL | |
| 10 mM | 0.4755 mL | 2.3776 mL | 4.7551 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
